SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 5 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar pchop123 (79.88) Submitted: 1/2/2013 11:05:32 AM : Outperform Start Price: $4.40 SCLN Score: +10.27

potential new acquisition ???

Featured Broker Partners


Advertisement